The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Ovarian Cancer: An Integrated Review
Abstract
OBJECTIVE To provide an overview of the risk factors, modifiable and non-modifiable, for ovarian cancer as well as prevention, diagnostic, treatment, and long-term survivorship concerns. This article will also examine current and future clinical trials surrounding ovarian cancer. DATA SOURCES A review of articles dated 2006-2018 from CINAHL, UpToDate, and National Comprehensive Cancer Network guidelines. CONCLUSION There is no screening test for ovarian cancer and with diagnosis often in the late stages, recurrence is high in this population. Early identification can range from knowing the vague symptoms associated with the cancer to prophylactic surgical removal of at-risk tissue. Standard treatment for ovarian cancer is surgery followed by combination chemotherapy. Although advances are being made, ovarian cancer remains the most fatal female gynecologic cancer. IMPLICATIONS FOR NURSING PRACTICE Becoming familiar with and educating women about risk factors and the elusive symptoms of ovarian cancer can increase patient autonomy and advocacy, as well as potentially improve patient outcomes for those affected by ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer
Walker, J. L., Powell, C. B., Chen, L., Carter, J., Bae Jump, V. L., Parker, L. P., Borowsky, M. E., & Gibb, R. K. (2015) · Cancer · doi:10.1002/cncr.29321 · Cited by 241
CHIEN, J. R., & Poole, E. M. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001118 · Cited by 105
Surgical prevention strategies in ovarian cancer
Mallen, A. R., Soong, T. R., Townsend, M. K., Wenham, R. M., Crum, C. P., & Tworoger, S. S. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.08.005 · Cited by 65
Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act
Tschernichovsky, R., & Goodman, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0444 · Cited by 61
Webb, P. M., Green, A. C., & Jordan, S. J. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0868-0 · Cited by 34
Huang, X., Wang, X., Shang, J., Lin, Y., Yang, Y., Song, Y., & Yu, S. (2018) · Journal of International Medical Research · doi:10.1177/0300060518792801 · Cited by 26
Different Patterns of Disease Spread between Advanced-Stage Type I and II Epithelial Ovarian Cancer
Bergamini, A., Candiani, M., Taccagni, G., Rabaiotti, E., Viganò, R., Marzi, P. D., Ferrari, D., & Mangili, G. (2015) · Gynecologic and Obstetric Investigation · doi:10.1159/000381261 · Cited by 9
Cited by
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer
Győrffy, B. (2023) · GeroScience · doi:10.1007/s11357-023-00742-4 · Cited by 381
Therapeutic Potential of Centella asiatica and Its Triterpenes: A Review
Sun, B., Wu, L., Wu, Y., Zhang, C., Qin, L., Hayashi, M., Kudo, M., Gao, M., & Liu, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.568032 · Cited by 353
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
“The prognosis of ovarian cancer patients is not optimistic, and the survival rate is merely 47.5% [226].”
InfluentialThe Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer
Nowak, M., & Klink, M. (2020) · Cells · doi:10.3390/cells9051299 · Cited by 287
Biological Function of Long Non-coding RNA (LncRNA) Xist
Wang, W., Min, L., Qiu, X., Wu, X., Liu, C., Ma, J., Zhang, D., & Zhu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645647 · Cited by 248
Piezo1 activation facilitates ovarian cancer metastasis via Hippo/YAP signaling axis
Xiong, Y., Dong, L., Bai, Y., Tang, H., Li, S., Luo, D., Liu, F., Bai, J., Yang, S., & Song, X. (2022) · Channels · doi:10.1080/19336950.2022.2099381 · Cited by 48
Cao, L., Wang, Y., Liu, J., Bai, X., & Chi, X. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13864 · Cited by 7
Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization
Garcia-del Rio, D. F., Derhourhi, M., Bonnefond, A., Leblanc, S., Guilloy, N., Roucou, X., Eyckerman, S., Gevaert, K., Salzet, M., & Cardon, T. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07046-1 · Cited by 7
Metadata
- Authors
- Stewart, C., Ralyea, C., & Lockwood, S.
- Venue
- Seminars in Oncology Nursing
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 35
- Issue
- 2
- Pages
- 151-156
- ISSN
- 0749-2081 (ISSN-L)
- OpenAlex
- W2922503148
- Cited by
- 1,090
- References
- 10
- FWCI
- 83.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.